February 2011 Br J Cardiol 2011;18:9-10
BJ Cardio Staff
The registry study, published in Journal of the American Medical Association (January 12th, 2011 issue), involved 30,254 patients, of whom 2,500 were taking losartan and 2,639 were taking candesartan. One-year survival was 90% for patients receiving candesartan and 83% for those taking losartan. Five-year survival was 61% and 44%, respectively. In multivariate analysis with adjustment for propensity scores, the hazard ratio for mortality for losartan compared with candesartan was 1.43 (p<0.001). The authors, led by Dr Maria Eklind-Cervenka (South Hospital, Stockholm, Sweden) note that the difference remained significant even after adjustme
January 2005 Br J Cardiol 2005;12:31-6
Hugh F McIntyre
No content available
May 2002 Br J Cardiol 2002;9:280-6
Simon W Dubrey
No content available
For healthcare professionals only
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits
